Acute Exacerbation of Interstitial Lung Disease: Definitions, Epidemiology, Prognosis and Management.

Mahmoud Alshneikat; Zaina Alnajjar; Osama Obeidat; Ahmad  AL-Tanjy; Amer Alsokhni; Ayoub Innabi

doi:10.58877/japaj.v2i1.125

Authors

Mahmoud Alshneikat
Zaina Alnajjar
Osama Obeidat Al-balqa Applied Univeristy
Ahmad AL-Tanjy
Amer Alsokhni
Ayoub Innabi

DOI:

https://doi.org/10.58877/japaj.v2i1.125

Abstract

Abstract

Acute exacerbation of interstitial ling disease (AE-ILD) denotes a rapid deterioration of respiratory function often leading to ICU admission due to severe hypoxemia. Definitions encompass the diverse spectrum of interstitial lung diseases and specific criteria for AE-ILD, originally established for idiopathic pulmonary fibrosis (IPF) and later expanded to other interstitial lung diseases. The incidence varies among the various interstitial lung disease subtypes, with around 10% of interstitial lung disease patients experiencing acute exacerbations within the initial two years of diagnosis. Clinical risk factors encompass advanced interstitial lung disease, compromised pulmonary function, and coexisting conditions.

Prognostic markers include baseline pulmonary parameters, blood markers, and a newly developed Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) staging system. However, due to the scarcity of randomized studies, optimal treatment strategies remain uncertain. Current guidelines propose supportive care and oxygen therapy, with cautious use of corticosteroids in AE-IPF. Antibiotics are employed to manage infections, with procalcitonin-guided therapy showing potential.

Management involves exposure elimination, targeted antibiotics, and antacid and antifibrotic use. For severe cases, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and even transplantation are considered.

To conclude, AE-ILD poses formidable challenges and high mortality rates. Given the lack of standardized approaches, the pursuit of randomized trials is vital to enhance the understanding and management of AE-ILD, optimizing patient outcomes within the ICU setting.

Keywords: acute exacerbation, interstitial lung disease, idiopathic pulmonary fibrosis, intensive care unit, definition.

References

Al-hameed FM, Sharma S. Outcome of Patients Admitted to Intensive Care Unit for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Can Respir J. NaN/NaN/NaN;11:117–22.

Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006 Jan 1;27(1):143–50.

Leuschner G, Behr J. Acute Exacerbation in Interstitial Lung Disease. Front Med. 2017 Oct 23;4:176.

Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011 Feb 1;37(2):356–63.

Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, et al. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2007 Oct;176(7):636–43.

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016 Aug;194(3):265–75.

Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, et al. Acute Exacerbation of Interstitial Pneumonia Other Than Idiopathic Pulmonary Fibrosis. Chest. 2007 Jul 1;132(1):214–20.

Suzuki A, Kondoh Y, Brown KK, Johkoh T, Kataoka K, Fukuoka J, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology. 2020;25(5):525–34.

Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014 Sep 1;15(1):109.

Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009 Jun;103(6):846–53.

Miyazaki Y, Tateishi T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y. Clinical Predictors and Histologic Appearance of Acute Exacerbations in Chronic Hypersensitivity Pneumonitis. Chest. 2008 Dec 1;134(6):1265–70.

Rice AJ, Wells AU, Bouros D, du Bois RM, Hansell DM, Polychronopoulos V, et al. Terminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias: An Autopsy Study. Am J Clin Pathol. 2003 May 1;119(5):709–14.

Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis–associated interstitial lung disease: clinical features and prognosis. Rheumatology. 2021 May 1;60(5):2348–54.

Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am J Roentgenol. 1997 Jan;168(1):79–83.

Olson AL, Huie TJ, Groshong SD, Cosgrove GP, Janssen WJ, Schwarz MI, et al. Acute Exacerbations of Fibrotic Hypersensitivity Pneumonitis: A Case Series. Chest. 2008 Oct 1;134(4):844–50.

Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015 Aug 1;46(2):512–20.

Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials. Respir Med. 2014 Feb 1;108(2):376–87.

Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14(1):73.

Bando M, Ohno S, Hosono T, Yanase K, Sato Y, Sohara Y, et al. Risk of Acute Exacerbation After Video-assisted Thoracoscopic Lung Biopsy for Interstitial Lung Disease. J Bronchol Interv Pulmonol. 2009 Oct;16(4):229.

Sakamoto S, Homma S, Mun M, Fujii T, Kurosaki A, Yoshimura K. Acute Exacerbation of Idiopathic Interstitial Pneumonia Following Lung Surgery in 3 of 68 Consecutive Patients: A Retrospective Study. Intern Med. 2011;50(2):77–85.

Samejima J, Tajiri M, Ogura T, Baba T, Omori T, Tsuboi M, et al. Thoracoscopic lung biopsy in 285 patients with diffuse pulmonary disease. Asian Cardiovasc Thorac Ann. 2015 Feb;23(2):191–7.

Amundson WH, Racila E, Allen T, Dincer HE, Tomic R, Bhargava M, et al. Acute exacerbation of interstitial lung disease after procedures. Respir Med. 2019 Apr 1;150:30–7.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788–824.

Kuhn C, Boldt J, King TE, Crouch E, Vartio T, McDonald JA. An Immunohistochemical Study of Architectural Remodeling and Connective Tissue Synthesis in Pulmonary Fibrosis. Am Rev Respir Dis. 1989 Dec;140(6):1693–703.

Dafforn TR, Della M, Miller AD. The Molecular Interactions of Heat Shock Protein 47 (Hsp47) and Their Implications for Collagen Biosynthesis *. J Biol Chem. 2001 Dec 28;276(52):49310–9.

Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2009 Apr;179(7):588–94.

Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Patients with Idiopathic Pulmonary Fibrosis with Antibodies to Heat Shock Protein 70 Have Poor Prognoses. Am J Respir Crit Care Med. 2013 Apr 1;187(7):768–75.

Johannson KA, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014 Apr;43(4):1124–31.

Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large Cohort Analysis. CHEST. 2016 May 1;149(5):1205–14.

Huie TJ, Olson AL, Cosgrove GP, Janssen WJ, Lara AR, Lynch DA, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: Aetiology and outcomes. Respirology. 2010;15(6):909–17.

Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-Acid Therapy and Disease Progression in Idiopathic Pulmonary Fibrosis: an analysis of data from three randomized controlled trials. Lancet Respir Med. 2013 Jul;1(5):369–76.

Simon-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet PY, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Outcome and Prognostic Factors. Respiration. 2011 Aug 23;83(1):28–35.

Petrosyan F, Culver DA, Reddy AJ. Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study. BMC Pulm Med. 2015 Jul 10;15(1):70.

Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012 Jun 1;41(6):e161–5.

Schupp JC, Binder H, Jäger B, Cillis G, Zissel G, Müller-Quernheim J, et al. Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. PLoS ONE. 2015 Jan 15;10(1):e0116775.

Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, et al. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis – Extended analysis of pirfenidone trial in Japan. Respir Investig. 2015 Nov 1;53(6):271–8.

Kondoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2010 Jul;27(2):103–10.

Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Dec 29;15:167.

Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012 Jul;40(1):93–100.

Kakiuchi S, Hanibuchi M, Tezuka T, Saijo A, Otsuka K, Sakaguchi S, et al. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1. Respir Investig. 2017 Mar 1;55(2):145–52.

Takei R, Arita M, Kumagai S, Ito Y, Noyama M, Tokioka F, et al. Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. BMC Pulm Med [Internet]. 2017 [cited 2023 Jul 20];17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397815/

Kishaba T, Tamaki H, Shimaoka Y, Fukuyama H, Yamashiro S. Staging of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis. Lung. 2014 Feb 1;192(1):141–9.

Charokopos A, Moua T, Ryu JH, Smischney NJ. Acute exacerbation of interstitial lung disease in the intensive care unit. World J Crit Care Med. 2022 Jan 9;11(1):22–32.

Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed Tomography Findings in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2008 Aug 15;178(4):372–8.

Tachikawa R, Tomii K, Ueda H, Nagata K, Nanjo S, Sakurai A, et al. Clinical Features and Outcome of Acute Exacerbation of Interstitial Pneumonia: Collagen Vascular Diseases-Related versus Idiopathic. Respiration. 2011 Sep 6;83(1):20–7.

Papiris SA, Kagouridis K, Kolilekas L, Papaioannou AI, Roussou A, Triantafillidou C, et al. Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach. BMC Pulm Med. 2015 Dec 14;15(1):162.

Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology. 2020;25(6):629–35.

Walkey AJ, Wiener RS. Macrolide Antibiotics and Survival in Patients With Acute Lung Injury. Chest. 2012 May;141(5):1153–9.

Kawamura K, Ichikado K, Suga M, Yoshioka M. Efficacy of Azithromycin for Treatment of Acute Exacerbation of Chronic Fibrosing Interstitial Pneumonia: A Prospective, Open-Label Study with Historical Controls. Respiration. 2014 Apr 30;87(6):478–84.

Ding J, Chen Z, Feng K. Procalcitonin-Guided Antibiotic Use in Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Int J Med Sci. 2013 May 20;10(7):903–7.

Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2011 Sep 22;365(12):1079–87.

Briones - Claudett KH, Claudett M, Domenica E, Garcia S, Solis J, Cabrera C, et al. Volume-Assured Pressure Support Mode Plus Pirfenidone as Resuscitation Therapy in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis. Adv Respir Med. 2020 Apr 30;88:147–52.

Toyoda Y, Hanibuchi M, Kishi J, Kawano H, Morizumi S, Sato S, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Invest. 2016;63(3.4):294–9.

Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Intern Med. 2010;49(2):109–15.

Homma S, Sakamoto S, Kawabata M, Kishi K, Tsuboi E, Motoi N, et al. Cyclosporin Treatment in Steroid-resistant and Acutely Exacerbated Interstitial Pneumonia. Intern Med. 2005;44(11):1144–50.

Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. N Engl J Med. 2015 Jun 4;372(23):2185–96.

Horio Y, Takihara T, Niimi K, Komatsu M, Sato M, Tanaka J, et al. High-flow nasal cannula oxygen therapy for acute exacerbation of interstitial pneumonia: A case series. Respir Investig. 2016 Mar 1;54(2):125–9.

Koyauchi T, Hasegawa H, Kanata K, Kakutani T, Amano Y, Ozawa Y, et al. Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders: A Retrospective Single-Center Study. Respiration. 2018 Jun 28;96(4):323–9.

Vianello A, Arcaro G, Battistella L, Pipitone E, Vio S, Concas A, et al. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care. 2014 Aug 1;29(4):562–7.

Yokoyama T, Kondoh Y, Taniguchi H, Kataoka K, Kato K, Nishiyama O, et al. Noninvasive Ventilation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Intern Med. 2010;49(15):1509–14.

Disayabutr S, Calfee CS, Collard HR, Wolters PJ. Interstitial lung diseases in the hospitalized patient. BMC Med. 2015 Sep 25;13(1):245.

Moerer O, Quintel M. Bridge or Abyss: Extracorporeal Membrane Oxygenation for Acute Respiratory Failure in Interstitial Lung Disease. Am J Respir Crit Care Med. 2016 Mar;193(5):474–6.

Todd EM, Roy SB, Hashimi AS, Serrone R, Panchanathan R, Kang P, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation: A single-center experience in the present era. J Thorac Cardiovasc Surg. 2017 Nov 1;154(5):1798–809.

Rangappa P, Moran JL. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. Crit Care Resusc J Australas Acad Crit Care Med. 2009 Jun;11(2):102–9.

Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of Patients with Idiopathic Pulmonary Fibrosis Admitted to the Intensive Care Unit. Am J Respir Crit Care Med. 2002 Sep 15;166(6):839–42.

Rush B, Wiskar K, Berger L, Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis. Respir Med. 2016 Feb 1;111:72–6.

Schrader M, Sathananthan M, Jeganathan N. Patients With Idiopathic Pulmonary Fibrosis Admitted to the ICU With Acute Respiratory Failure—A Reevaluation of the Risk Factors and Outcomes. J Intensive Care Med. 2022 Mar 1;37(3):342–51.

Gaudry S, Vincent F, Rabbat A, Nunes H, Crestani B, Naccache JM, et al. Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia. J Thorac Cardiovasc Surg. 2014 Jan 1;147(1):47–53.